J Gynecol Oncol.  2023 Nov;34(6):e82. 10.3802/jgo.2023.34.e82.

Optimal number of neoadjuvant chemotherapy cycles prior to interval debulking surgery in advanced epithelial ovarian cancer: a systematic review and meta-analysis of progression-free survival and overall survival

• Coada CA
• Dondi G
• Ravegnini G
• Costanzo SD
• Tesei M
• Fiuzzi E
• Stanislao MD
• Giunchi S
• Zamagni C
• Bovicelli A
• Hrelia P
• Angelini S
• Iaco PD
• Perrone AM

• KMID: 2552659
• DOI: http://doi.org/10.3802/jgo.2023.34.e82

Abstract

Objective
Neoadjuvant chemotherapy (NACT) represents a treatment option in patients with advanced epithelial ovarian cancer (AEOC) who are not good candidates for primary debulking surgery. Usually, 3 cycles of chemotherapy before surgery have been considered the best option for patient survival, although quite often some patients receive more than 3 cycles. The aim of this systematic review and meta-analysis was to identify the optimal number of NACT cycles reporting better survival in AEOC patients.
Methods
PubMed, Cochrane Library, and Scopus were searched for original articles that analyzed the relationship between the number of chemotherapy cycles and clinical outcomes in AEOC patients before interval debulking surgery (IDS). The main outcomes were progression-free survival (PFS) and overall survival (OS).
Results
A total of 22 studies comprising 7,005 patients diagnosed with AEOC were included in our analysis. In terms of survival, the reviewed studies dividing the patients in ≤3 NACT cycles vs. >3, showed a trend for a decrease in PFS and a significant reduction in OS with an increasing number of cycles, while a difference in both PFS and OS was revealed if early IDS included patients with 4 NACT cycles. These results should be interpreted with caution due to the complex characteristics of AEOC patients.
Conclusion
In conclusion, our review and meta-analysis revealed that there is not enough evidence to determine the optimal number of NACT treatments before surgery. Further research in the form of well-designed randomized controlled trials is necessary to address this issue.

Keyword

Neoadjuvant Chemotherapy; Prognosis; Ovarian Cancer; Cytoreductive Surgery; Survival